We came across a bullish thesis on Nektar Therapeutics on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NKTR. Nektar Therapeutics's share was trading at $35.23 as of January 29th.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. NKTR has strengthened its immunology platform with new data that expands the potential of its lead asset, Rezpegaldesleukin (Rezpeg), and widens...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.